A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.

ABSTRACT:

Background

Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials.

Methods

We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient's clinical status 30 days after the intervention, as measured on a six-point ordinal scale ranging from total recovery to death.

Results

A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile ran

SUBMITTER: Simonovich VA 

PROVIDER: S-EPMC7722692 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature